A Phase 1 interventional study of Clopidogrel in Bioequivalence, AUC, Cmax, Pharmacokinetics, sponsored by AstraZeneca. Completed at 1 site in Germany. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-06-22.
Sponsored by AstraZeneca · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will be an open-label, randomised, three-way crossover study in healthy male and female subjects, performed at a single centre. The objective of the study is to assess the bioequivalence between one test formulation (Clopidogrel 75 mg tablet (commercial blister from KRKA) and two reference formulations (Clopidogrel 75 mg tablet [Plavix, sourced in US and Japan]).
Study to evaluate the bioequivalence of orally administered European source clopidogrel tablets and US and Japanese source clopidogrel tablets.
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Females must have a negative pregnancy test at screening and on each admission to the clinical unit, must not be lactating and
Documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation.
Exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment A: a single oral dose of clopidogrel 75 mg film-coated tablet (Zyllt, KRKA - test)
Drug: Clopidogrel
Treatment B: a single oral dose of clopidogrel 75 mg film-coated tablet (Plavix®, Brystol-Myer Squibb,Sanofi-Aventis, reference)
Drug: Clopidogrel
Treatment C: a single oral dose of clopidogrel 75 mg film-coated tablet (Plavix®, Sanofi-Aventis, reference)
Drug: Clopidogrel
European clopidogrel tablets, 75 mg (test) versus Japanese clopidogrel tablets, 75 mg (reference); European clopidogrel tablets, 75 mg (test) versus US clopidogrel tablets, 75 mg (reference)
Also known as: Zyllt, Plavix
Pharmacokinetics of Clopidogrel by Assessment of Area Under the Curve From Time Zero Extrapolated to Infinity (AUC(0-inf))
Comparison of the pharmacokinetic profile in terms of plasma concentration-time curve from time zero extrapolated to infinity, AUC(0-inf), of clopidogrel sourced in Europe and Japan.
Time frame: 0 hours (pre-dose), as well as at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24 and 36 hours post-dose
Pharmacokinetics of Clopidogrel by Assessment of Observed Maximum Plasma Concentration (Cmax)
Comparison of the pharmacokinetic profile in terms of observed maximum plasma concentration, taken directly from the individual concentration-time curve, Cmax, of clopidogrel sourced in Europe and the US.
Time frame: 0 hours (pre-dose), as well as at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24 and 36 hours post-dose
Pharmacokinetics of Clopidogrel by Assessment of Area Under the Curve From Time Zero to the Time of Last Quantifiable Concentration (AUC(0-last))
Comparison of the pharmacokinetic profile in terms of the area under the plasma concentration-curve from time zero to the time of last quantifiable clopidogrel or SR26334 concentration, AUC(0-last), of clopidogrel sourced in Europe and the US.
Time frame: 0 hours (pre-dose), as well as at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24 and 36 hours post-dose
Participants recruited at PAREXEL Early Phase Clinical Unit Berlin, Germany between August 2014 and September 2014.
| Milestone | First European, Then Japanese, Then US Clopidogrel | First European, Then US, Then Japanese Clopidogrel | First Japanese, Then European, Then US Clopidogrel | First Japanese, Then US, Then European Clopidogrel | First US, Then European, Then Japanese Clopidogrel | First US, Then Japanese, Then European Clopidogrel |
|---|---|---|---|---|---|---|
| Started | 14 | 14 | 14 | 14 | 14 | 14 |
| Completed | 14 | 14 | 14 | 13 | 14 | 14 |
| Not completed | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 | 0 | 0 |
| Milestone | First European, Then Japanese, Then US Clopidogrel | First European, Then US, Then Japanese Clopidogrel | First Japanese, Then European, Then US Clopidogrel | First Japanese, Then US, Then European Clopidogrel | First US, Then European, Then Japanese Clopidogrel | First US, Then Japanese, Then European Clopidogrel |
|---|---|---|---|---|---|---|
| Started | 14 | 14 | 14 | 13 | 14 | 14 |
| Completed | 13 | 14 | 14 | 13 | 13 | 13 |
| Not completed | 1 | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 1 |
| Milestone | First European, Then Japanese, Then US Clopidogrel | First European, Then US, Then Japanese Clopidogrel | First Japanese, Then European, Then US Clopidogrel | First Japanese, Then US, Then European Clopidogrel | First US, Then European, Then Japanese Clopidogrel | First US, Then Japanese, Then European Clopidogrel |
|---|---|---|---|---|---|---|
| Started | 13 | 14 | 14 | 13 | 13 | 13 |
| Completed | 13 | 14 | 14 | 13 | 13 | 13 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | First European, Then Japanese, Then US Clopidogrel | First European, Then US, Then Japanese Clopidogrel | First Japanese, Then European, Then US Clopidogrel | First Japanese, Then US, Then European Clopidogrel | First US, Then European, Then Japanese Clopidogrel | First US, Then Japanese, Then European Clopidogrel |
|---|---|---|---|---|---|---|
| Started | 13 | 14 | 14 | 13 | 13 | 13 |
| Completed | 13 | 14 | 14 | 13 | 13 | 13 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | First European, Then Japanese, Then US Clopidogrel | First European, Then US, Then Japanese Clopidogrel | First Japanese, Then European, Then US Clopidogrel | First Japanese, Then US, Then European Clopidogrel | First US, Then European, Then Japanese Clopidogrel | First US, Then Japanese, Then European Clopidogrel |
|---|---|---|---|---|---|---|
| Started | 13 | 14 | 14 | 13 | 13 | 13 |
| Completed | 13 | 14 | 14 | 13 | 13 | 13 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
Comparison of the pharmacokinetic profile in terms of plasma concentration-time curve from time zero extrapolated to infinity, AUC(0-inf), of clopidogrel sourced in Europe and Japan.
| ng*h/mL | European Clopidogrel Tablets, 75 mg | Japanese Clopidogrel Tablets, 75 mg | US Clopidogrel Tablets, 75 mg |
|---|---|---|---|
| Pharmacokinetics of Clopidogrel by Assessment of Area Under the Curve From Time Zero Extrapolated to Infinity (AUC(0-inf)) | 1.05 ± 139.0 | 0.992 ± 117.9 | 1.09 ± 106.9 |
Comparison of the pharmacokinetic profile in terms of observed maximum plasma concentration, taken directly from the individual concentration-time curve, Cmax, of clopidogrel sourced in Europe and the US.
| ng/mL | European Clopidogrel Tablets, 75 mg | Japanese Clopidogrel Tablets, 75 mg | US Clopidogrel Tablets, 75 mg |
|---|---|---|---|
| Pharmacokinetics of Clopidogrel by Assessment of Observed Maximum Plasma Concentration (Cmax) | 0.551 ± 122.6 | 0.511 ± 150.6 | 0.521 ± 122.4 |
Comparison of the pharmacokinetic profile in terms of the area under the plasma concentration-curve from time zero to the time of last quantifiable clopidogrel or SR26334 concentration, AUC(0-last), of clopidogrel sourced in Europe and the US.
| h*ng/mL | European Clopidogrel Tablets, 75 mg | Japanese Clopidogrel Tablets, 75 mg | US Clopidogrel Tablets, 75 mg |
|---|---|---|---|
| Pharmacokinetics of Clopidogrel by Assessment of Area Under the Curve From Time Zero to the Time of Last Quantifiable Concentration (AUC(0-last)) | 0.705 ± 114.8 | 0.751 ± 116.5 | 0.767 ± 107.1 |
Collected over From screening until follow-up, i.e. up to 7 weeks after the first dose.. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| European Clopidogrel Tablets, 75 mg | — | 0/81 (0%) | 19/81 (23.5%) |
| Japanese Clopidogrel Tablets, 75 mg | — | 0/80 (0%) | 18/80 (22.5%) |
| US Clopidogrel Tablets, 75 mg | — | 0/82 (0%) | 22/82 (26.8%) |
| Total Number of Participants | — | 0/83 (0%) | 38/83 (45.8%) |
| Event | European Clopidogrel Tablets, 75 mg | Japanese Clopidogrel Tablets, 75 mg | US Clopidogrel Tablets, 75 mg | Total Number of Participants |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 0/81 | 1/2 | 2/2 | 3/4 |
| HeadacheNervous system disorders | 16/81 | 15/80 | 16/82 | 29/83 |
| DizzinessNervous system disorders | 0/81 | 1/80 | 3/82 | 4/83 |
| Abdominal PainGastrointestinal disorders | 1/81 | 1/80 | 1/82 | 3/83 |
| Catheter Site PainGeneral disorders | 0/81 | 2/80 | 0/82 | 2/83 |
| NauseaGastrointestinal disorders | 0/81 | 0/80 | 2/82 | 2/83 |
| NasopharyngitisInfections and infestations | 0/81 | 0/80 | 2/82 | 2/83 |
| ContusionInjury, poisoning and procedural complications | 1/81 | 0/80 | 1/82 | 2/83 |
| PresyncopeNervous system disorders | 0/81 | 1/80 | 0/82 | 1/83 |
| FatigueGeneral disorders | 1/81 | 0/80 | 0/82 | 1/83 |
The overall number of baseline participants is 84, as it comprised all randomized subjects, although one subject withdrew consent prior to the first dose. Thus the safety population includes 83 subjects only.
| Age, Continuous(years) | First European, Then Japanese, Then US Clopidogrel | First European, Then US, Then Japanese Clopidogrel | First Japanese, Then European, Then US Clopidogrel | First Japanese, Then US, Then European Clopidogrel | First US, Then European, Then Japanese Clopidogrel | First US, Then Japanese, Then European Clopidogrel | Total |
|---|---|---|---|---|---|---|---|
| Mean | 33 ± 9 | 37 ± 11 | 36 ± 10 | 35 ± 8 | 34 ± 9 | 36 ± 11 | 35 ± 9 |
| Sex: Female, Male(Participants) | First European, Then Japanese, Then US Clopidogrel | First European, Then US, Then Japanese Clopidogrel | First Japanese, Then European, Then US Clopidogrel | First Japanese, Then US, Then European Clopidogrel | First US, Then European, Then Japanese Clopidogrel | First US, Then Japanese, Then European Clopidogrel | Total |
|---|---|---|---|---|---|---|---|
| Female | 7 | 7 | 8 | 7 | 4 | 4 | 37 |
| Male | 7 | 7 | 6 | 7 | 10 | 10 | 47 |
| Race/Ethnicity, Customized(participants) | First European, Then Japanese, Then US Clopidogrel | First European, Then US, Then Japanese Clopidogrel | First Japanese, Then European, Then US Clopidogrel | First Japanese, Then US, Then European Clopidogrel | First US, Then European, Then Japanese Clopidogrel | First US, Then Japanese, Then European Clopidogrel | Total |
|---|---|---|---|---|---|---|---|
| Black or African American | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| White | 13 | 14 | 13 | 14 | 12 | 13 | 79 |
| Other | 0 | 0 | 1 | 0 | 2 | 1 | 4 |
| Race/Ethnicity, Customized(participants) | First European, Then Japanese, Then US Clopidogrel | First European, Then US, Then Japanese Clopidogrel | First Japanese, Then European, Then US Clopidogrel | First Japanese, Then US, Then European Clopidogrel | First US, Then European, Then Japanese Clopidogrel | First US, Then Japanese, Then European Clopidogrel | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 2 | 1 | 3 |
| Not Hispanic or Latino | 14 | 14 | 14 | 14 | 12 | 13 | 81 |
| BMI (Body Mass Index)(kg/m^2) | First European, Then Japanese, Then US Clopidogrel | First European, Then US, Then Japanese Clopidogrel | First Japanese, Then European, Then US Clopidogrel | First Japanese, Then US, Then European Clopidogrel | First US, Then European, Then Japanese Clopidogrel | First US, Then Japanese, Then European Clopidogrel | Total |
|---|---|---|---|---|---|---|---|
| Mean | 23.7 ± 3.1 | 24.7 ± 3.5 | 23.4 ± 2.9 | 24.1 ± 2.7 | 23.0 ± 3.1 | 23.9 ± 3.1 | 23.8 ± 3.0 |
The record gives a start of Aug 2014, a primary completion of Oct 2014 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2015, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Clopidogrel